Boryung, acquires domestic sales rights for Lilly's GemZar

Strengthening anticancer drug portfolio

GemZar

Boryung acquired the domestic right for the anticancer drug 'GemZar (Gemcitabine HCl)' held by Eli Lilly.

 

Boryung announced on the 8th that it had signed a contract to transfer assets to Eli Lilly and Gemzar.

 

Through this agreement, Boryung has all rights, including domestic rights and licenses of Gemzar.

 

Boryung and Eli Lilly have been conducting 'Gemzar' co-promotion since 2015.

 

Gemzar is widely used in pancreatic cancer, non-small cell lung cancer, bladder cancer, breast cancer, ovarian cancer, and biliary tract cancer.

 

It is used alone or in combination therapy in primary and secondary treatment.

 

As of last year, Gemzar's domestic sales totaled ₩14.2 billion (based on IMS).

 

Boryung expects to strengthen its anticancer drug portfolio and maximize its market share and profit margin.

 

Currently, Boryung has a high market share in the domestic anticancer drug market with Oxalitin (Oxaliplatin) and Genexol (Paclitaxel).

 

As of the fourth quarter of last year, among domestic pharmaceutical companies, it ranked No.

 

1 in the market for anti-tumor drugs and immunomodulators.

 

David A.

 

Ricks, chief executive officer of Eli Lilly said "I hope this contract will help further improve the treatment performance of Korean cancer patients," Jae-Hyun Ahn, Boryung’s CEO, emphasized, "Boryung, which is building the best anti-cancer drug business in Korea, can strengthen the line-up of anti-cancer drugs and make more stable profits with this brand acquisition." He said, "In the future, we will strengthen our portfolio for the anti-cancer area as well as grow it as a representative business of Boryung through active investment such as open innovation."